How should we be defining a meaningful clinical response to TNF-blockers in ankylosing spondylitis patients?
Reference:
Stone, M., Cortinovis, D., Raj, A. G., Maetzel, A., Inman, R., Lapp, V. and Beaton, D., 2006. How should we be defining a meaningful clinical response to TNF-blockers in ankylosing spondylitis patients? Annals of the Rheumatic Diseases, 65, p. 544.
Related documents:
This repository does not currently have the full-text of this item.You may be able to access a copy if URLs are provided below.
Details
| Item Type | Articles |
| Creators | Stone, M., Cortinovis, D., Raj, A. G., Maetzel, A., Inman, R., Lapp, V. and Beaton, D. |
| Departments | Faculty of Humanities & Social Sciences > Health Faculty of Science > Pharmacy & Pharmacology |
| Refereed | Yes |
| Status | Published |
| ID Code | 6374 |
| Additional Information | ID number: ISI:000249372502252 |
Export
Actions (login required)
| View Item |
